Assessing the impact of rarity on French HTA and pricing decisions
With changes to the pricing and access processes such as the new Accord Cadre and the soon-to-be implemented ATU reform likely to impact pricing and access of...
This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
Cécile Matthews is a vice president in the Life Sciences Practice and has 20 years of experience in strategy consulting for the life sciences industry.
Cécile Matthews leverages her expertise in pricing and market access to provide her clients with strategic insights on how to best prepare for launch and optimize revenues. Her areas of expertise include pricing, reimbursement, and market access on issues affecting biopharmaceuticals globally. She has deep experience working in oncology and rare diseases.
In oncology, Cécile has completed many assignments on i-os, targeted therapies, biosimilars, and companion diagnostics tackling issues such as early access, launch sequence, drivers of access, global pricing and access strategies, and launch readiness activities. In rare diseases, she has advised and published on issues such as early access, leveraging patient involvement, strategies to address uncertainty of evidence, and global pricing and market access strategies. She is particularly renowned for her expert knowledge of France.
Throughout her consulting career, Cécile has worked with clients on many aspects of the life science industry including biopharmaceuticals, medical devices, vaccines, and mobile health applications. Before joining CRA, Cécile was a principal at Eradigm Consulting, an insights and strategy consulting firm, and worked as an independent consultant and at Cambridge Pharma Consultancy/IMS Pricing and Reimbursement, now IQVIA.
Cécile is a dual French/British national.